Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2

Figure 4

The effects of ERK1/2 and JNK signaling in endometrial cancer cells. (A) The effects of GnRH-II on ERK1/2 and JNK signaling activation. The cells were treated with GnRH-II (1 μM) at different time points. The phosphorylated ERK1/2 (p-ERK1/2), and phosphorylated JNK (p-JNK) levels were analyzed by immunoblot analysis, which indicated increases in the levels of p-ERK1/2 and p-JNK following 5 min of stimulation. (B) The effects of human si-GnRH-IR transfection on the GnRH-II-induced activation of ERK1/2 and JNK. The activation of ERK1/2 and JNK induced by GnRH-II (GII) was investigated after si-GnRH-IR transfection and showed significant decreases in the levels of p-ERK1/2 and p-JNK. (C) The effects of U0126 and SP600125 pretreatment on GnRH-II-induced ERK1/2 and JNK activation. Cells were pretreated individually with 1 μM U0126 or 1 μM SP600125 for 30 min followed by stimulation with 1 μM GnRH-II for 10 min. The control culture was treated with DMSO as a vehicle control. Pretreatment with 1 μM U0126 and 1 μM SP600125 individually attenuated the effects of GnRH-II on the induction of cell migration and invasion. (Columns, mean from three independent experiments in three different passages of the cell line; bars, SE., *p<0.05, versus control; #p<0.05, versus GnRH-II).

Back to article page